# BBOpCo (NCT06268015)

> Botensilimab and Balstilimab Optimization in Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06268015
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Nicholas DeVito, MD
- Conditions: Colorectal Cancer
- Interventions: Botensilimab; Balstilimab; Oxaliplatin; Leucovorin; Fluorouracil; Bevacizumab; Panitumumab
- Enrollment: 16
- Primary outcome: Disease control rate based on iRECIST at second restaging scan
- Primary outcome: Proportion of subjects with a best overall response of complete response or partial response according to iRECIST

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 4
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bbopco-nct06268015